Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Rollover Protocol For Patients Who Received Tremelimumab (CP-675,206 ) In Other Protocols

NCT00378482 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00378482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00378482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Rollover Protocol For Patients Who Received Tremelimumab (CP-675,206 ) In Other Protocols
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
March 5, 2007
Completion date
October 27, 2023
Enrollment
37 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms, melanoma, neoplasms, patients who have/have had melanoma and other tumors, prostatic neoplasms, renal cell carcinoma